Company intelligence / Profile preview
Starget Pharma
- Ownership
- Private
- Development stage
- Phase 1
Overview
Starget Pharma has achieved first-in-human data with its lead peptide radioligand program targeting SSTR3, demonstrating promising safety and tumor uptake. The company is preparing for a Phase 1b trial at MD Anderson Cancer Center and other sites in early 2025. Its proprietary platform enables rapid development of highly specific, stable, and selective peptide-based radiotherapeutics for difficult-to-treat cancers[5][6].
- Therapeutic areas
- Oncology
- Modalities
- Peptide-based radioligandsRadiopharmaceuticals (Smart Targeted Radioligands, STRs)Theranostics (diagnostic and therapeutic radioligands)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Starget Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Starget Pharma.